Browsing by Author "Senior, Roxy"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial
    (Wiley, 2021-07) Lang, Ninian N.; Ahmad, Faheem A.; Cleland, John G.; O'Connor, Christopher M.; Teerlink, John R.; Voors, Adriaan A.; Taubel, Jorg; Hodes, Anke R.; Anwar, Mohamed; Karra, Ravi; Sakata, Yasushi; Ishihara, Shiro; Senior, Roxy; Khemka, Abhishek; Prasad, Narayana G.; DeSouza, Mary M.; Seiffert, Dietmar; Ye, June Y.; Kessler, Paul D.; Borentain, Maria; Solomon, Scott D.; Felker, G. Michael; McMurray, John J. V.; Medicine, School of Medicine
    Aims Nitroxyl provokes vasodilatation and inotropic and lusitropic effects in animals via post-translational modification of thiols. We aimed to compare effects of the nitroxyl donor cimlanod (BMS-986231) with those of nitroglycerin (NTG) or placebo on cardiac function in patients with chronic heart failure with reduced ejection fraction (HFrEF). Methods and results In a randomized, multicentre, double-blind, crossover trial, 45 patients with stable HFrEF were given a 5 h intravenous infusion of cimlanod, NTG, or placebo on separate days. Echocardiograms were done at the start and end of each infusion period and read in a core laboratory. The primary endpoint was stroke volume index derived from the left ventricular outflow tract at the end of each infusion period. Stroke volume index with placebo was 30 ± 7 mL/m2 and was lower with cimlanod (29 ± 9 mL/m2; P = 0.03) and NTG (28 ± 8 mL/m2; P = 0.02). Transmitral E-wave Doppler velocity on cimlanod or NTG was lower than on placebo and, consequently, E/e′ (P = 0.006) and E/A ratio (P = 0.003) were also lower. NTG had similar effects to cimlanod on these measurements. Blood pressure reduction was similar with cimlanod and NTG and greater than with placebo. Conclusion In patients with chronic HFrEF, the haemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.